http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Kyoung Chan,Kim, Kyu Han,Ahn, Jong Seong,Chung, Jin Ho,Youn, Jai Il,Whang, Ji Hwan,Youn, Sang Woong,Kim, Young Gull,Koh, Woo Seok,Jung, Hyun Chae 대한피부과학회 1997 Annals of Dermatology Vol.9 No.4
Backgrounds : It was demonstrated that ultraviolet(UV) B light induces the release of IL-la in cultured human epithelial cell line and augmentation of GM-CSF production by UVB is reported to be mediated by IL-1α in the murine keratinocyte cell line Pam 212. Objective : The purpose of this study was to evaluate the effects of UVB on kinetic profile of IL-1 and GM-CSF mRNA expression and to see whether synthesis of GM-CSF by UVB can be completely inhibited by blocking IL-1α mediated pathway. Method : We used a competitive RT-PCR for measuring cytokine gene expression in epithelial cell line after UV radiation. Results : The IL-1α mRNA increased as early as 1h after UV irradiation, and then decreased at 3h after the irradiation. Thereafter, the response of IL-1α mRNA was upregulated with a second peak at 6h after the UV irradiation. However, mRNA for GM-CSF increased at 1h after UV light exposure and anti-IL-1α antibodies could only partially inhibit UV-augmented GMCSF production. Conclusion : UVB induced GM-CSF production seemed to be mainly mediated by UVB induced IL-1α but these results suggest that UVB may also induce GM-CSF production through an IL-1α independent pathway.
인체 각질형성세포의 Interleukin-6 생산에 미치는 UVB, UVA 및 PUVA의 영향
고우석,김규한,정진호,윤상호,윤재일,은희철 大韓免疫學會 1996 大韓免疫學會誌 Vol.18 No.3
Huma Keratinocytes are capable of producing a wide variety of cytokines and growth factors that may act as mediator in an immune response and play an important role in proliferation and repair. Production of epidermal cytokines may be induced by bacterial products, by other proinflammatory cytokines, or by physical alteration including ultraviolet radiation. In the present study, we investigated the effect of UVA and PUVA on the production of IL-6 by cultured human keratinocyte. Human keratinocytes derived from normal foreskin were treated with various dose of UVB, UVA and PUVA. With the irradiated keratinocytes or culture supernatant we measured the expression of IL-6 mRNA and the production of IL-6. The result of - the present study was that the UVB increased the production of IL-6 but UVA and PUVA didn't increase the production of IL-6 by human keratinocyte.
자외선 조사 후의 인체 각질형성세포에서의 IL-1 생산 및 Retinoid가 이에 미치는 영향
정진호,은희철,윤재일 大韓免疫學會 1993 大韓免疫學會誌 Vol.15 No.-
The purpose of this study is to observe the effect of UVB and retinoid on the production of IL-1 in cultured human keratinocytes and to determine whether retinoid can influence the effect of UVB on the IL-1 production. Human keratinocytes derived from normal foreskin were treated with various dose of UVB(0-100mJ/cm2) or retinol acetate(0-5 x 10-6M) and cultured for 1-3 days. IL-i levels in the culture supernatants and cell extracts of the cultured keratinocytes were measured by thymocyte costimulation assay. We demonstrated that UVB and retinol acetate increased the production of IL-1 by human keratinocytes, and the stimulatory effect of UVB on the production of IL -1 in keratinncvt.es was also increased by retinnl acetate.
Paradoxical psoriasis induced by biologic therapies
( Hyun Yi Suh ),( Hong Lim Kim ),( Kyung Ho Kim ),( Jae Wook Jeon ),( Ji Young Ahn ),( Mi Youn Park ),( Jai Il Youn ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.1
Biologic therapies currently approved for the treatment of moderate-to-severe plaque psoriasis work well. Administrations of those are beneficial in a variety of chronic inflammatory conditions. Recent reports have illustrated the paradoxical development of psoriasis after biologic therapies. A 30-year-old man presented widespread scaly erythematous patches on the whole body involvement after treatment with the third dose of infliximab. He was diagnosed with palmoplantar psoriasis 6 years ago. The patients had been treated either neotigason or cyclosporine with eximer phototherapy for 2 years 6 months before visiting our psoriasis clinic. He was started on the injections of infliximab, but there was no improvement after the first dose. After receiving third dose of infliximab, the patient had experienced worsening of his plaque psoriasis on the whole. We changed other biologics, ustekinumab, anti-IL-12/23 p40 monoclonal antibody. He was treated with ustekinumab. Although receiving the second dose of ustekinumab, the skin lesions were not improved and worsening of appearing pustules on the palm and sole. We treated with cyclosporin and with calcipotriol agent (Daivonex® cream) for his skin lesion. Herein, we report this impressive case of induced paradoxical psoriasis after treating on TNF-a inhibitor and IL-12/23 inhibitor.
( Jin Young Moon ),( Dong Jin Go ),( Jae Hyun Lee ),( Jin Kyun Park ),( Eun Bong Lee ),( Yeong Wook Song ),( Jai Il Youn ),( Eun Young Lee ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Nowadays, tumor necrosis factor-a (TNF-a) blockers are used for the treatment of RA, infi ammatory bowel diseases (IBD), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. Paradoxically, there are some reports of appearance of psoriasis after TNF-a blockers. We report a patient who have seronegative mono-rheumatoid arthritis (mono-RA) on knee joint that experienced psoriasis after TNF-a blocker therapy (adalimumab and etanercept). For the patient, oral medication is not available due to intolerance; thus, we tried ustekinumab which is an anti-IL-12/23 monoclonal antibody that has been used to treat psoriasis. After ustekinumab injection, psoriatic skin lesions and joint symptoms were much improved in the patient. But in the following period, joint pain and swelling aggravated and synovial fi uid cytokine levels such as IL-6 and IL-17 were elevated. Treatment was changed to tocilizumab, humanized monoclonal antibody against IL-6 receptor. After injection, knee joint swelling rapidly subsided without worsening of psoriatic skin lesion.
( Jinyoung Moon ),( Nakwon Kwak ),( Jin Lim ),( Dong Jin Go ),( Jae Hyun Lee ),( Jin Kyun Park ),( Eun Bong Lee ),( Yeong Wook Song ),( Jai Il Youn ),( Eun Young Lee ) 대한류마티스학회 2015 대한류마티스학회지 Vol.22 No.4
Nowadays, tumor necrosis factor-α (TNF-α) blockers are used for treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Paradoxically, there are some reports on the appearance of psoriasis after administration of TNF-α blockers. Here, we report on a patient with monoarthritis in a knee joint who experienced psoriasis after TNF-α blocker therapy (adalimumab and etanercept). Oral medication was not a treatment option due to patient intolerance; thus, we tried ustekinumab, an anti-interleukin (IL)-12/23 monoclonal antibody used for treatment of psoriasis. Following ustekinumab injection, psoriatic skin lesions and joint symptoms were much improved. However, in the following period, joint pain and swelling became aggravated and synovial fluid cytokine levels including IL-6 and IL-17 were elevated. The treatment was changed to tocilizumab, a humanized monoclonal antibody against IL-6 receptor. After injection, knee joint swelling rapidly subsided without worsening of psoriatic skin lesions. (J Rheum Dis 2015;22:263-268)
조갑진균증에서 Ciclopirox Nail Lacquer의 치료효과
박경찬,김정애,방형돈,조광현,윤재일,김병수 대한감염학회 1995 감염 Vol.27 No.3
배경 및 목적:조갑진균증의 치료에 있어 국소용 항진균제는 조갑판을 통과하지 못하기 때문에 치료율이 낮은 것으로 알려졌으나 최근 조갑판을 통과하여 조상에서도 높은 치료농도를 유지할 수 있는 국소용 항진균제인 ciclopirox nail lacquer가 개발되었다. 이에 본 저자들은 8% ciclopirox nail lacquer 단독 도포의 조갑진균증에서의 치료 효과와 안전성을 알아 보기 위한 연구를 수행하였다. 방법:표적 조갑판의 감염된 면적의 비율이 50%이하인 경증의 조갑진균증 환자 27명을 평가 대상으로 하였으며 8% ciclopirox nail lacquer 1일 1회 도포요법으로 6개월간 치료하였다. 매 방문시마다 감염면적 비율을 기록하였고 치료 전과 치료 후 진균 검사를 시행하였다. 결과: 1)표적조갑판의 감염 면적이 치료 전 평균 28.9%에서 치료 종료시 4.7%로 통계적으로 유의하게 감소하였다(p<0.001). 2)KOH 직접 도말 검사와 진균 배양 검사에서 모두 음성인 진균학적 완치율은 치료 종료시 77.8%였다. 3)부작용으로는 3명(11.1%)에서 일시적 작열감, 조갑 감입 등을 호소하였다. 결론:경증의 조갑진균증 치료에 있어 8% ciclopirox nail lacquer는 비교적 좋은 치료 효과를 보이며 부작용이 적은 약제로 생각된다. Background: Topical antifungal agents have been ineffective in the treatment of onychomycosis because they could not reach the infected nail bed. 8% ciclopirox nail lacquer is a new topical antimycotic which is characterized by excellent penetration into the nail plate. We performed a study to assess the therapeutic efficacy and safety of 8% ciclopirox nail lacquer in the treatment of onychomycosis. Methods: We assessed 27 onychomycotic patients whose affected area of target nail plate was not more than 50%. The patients were instructed to apply 8% ciclopirox nail lacquer once daily and evaluated monthly for 6 months. Mycological examinations were done before and after the treatment. Overall efficacy, tolerability, cosmetic acceptance and adverse effects were assessed at the end of 6 months' treatment. Results: The mean percentage of affected area decreased from 28.9% to 4.7%. Mycological cure rate was 77.8% at the end of the treatment. Overall efficacy assessed by physician and patients were similar and evaluated as complete cure in 48% and 44%, respectively. Tolerability and cosmetic acceptance were excellent or good in most of the patients. No systemic adverse effects were found, but 3 patients complained of mild prickling sensation or ingrowing toe nail. Conclusions: These data suggest that 8% ciclopirox nail lacquer is safe and effective in the treatment of mild onychomycosis.